Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.
about
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse eventsA Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 InfectionFanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patientsHigher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.Cardiovascular disease in HIV patients: from bench to bedside and backwards.Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s.Ageing with HIV: a multidisciplinary review.Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines.Risk factors contributing to a low darunavir plasma concentration.What do we know about tailoring treatment with tenofovir?
P2860
Q28535587-726BEE54-45DF-42A7-8CDA-27987BFF7244Q28552839-10830B51-B585-4A79-9831-049AB4CA1C79Q35126728-3F8820DC-37DB-42CC-84A3-6FEEF9DE61CDQ35134488-89DFB95E-EFB2-4307-B4BD-EFF5B18C0512Q35203971-B7309AF7-7252-48E3-986D-801D9BDF2C0DQ35652795-B4FAD679-B090-4321-B36F-B0D24173946CQ38490362-6DE382EB-DCE6-425D-9342-D6A8F14B0854Q38527537-64FFCFF1-7AF8-4B66-B5F9-88F06714392AQ38661064-C5450C55-7006-4A3D-B265-BC619FC3527FQ39074109-A2C89E29-27B4-4D7F-892F-0B91F4747175Q39196660-F7827762-2DED-4E5E-BDF2-D99673DE42F7Q40379981-D12391A7-602F-46EF-8E79-3CC3CE9AC935Q40462001-8468DEB0-374E-4110-82FB-AEEB2277DD1BQ47232203-80B686C9-409D-40F2-9392-F9B724943FACQ54624919-43186DC2-3A8E-41F7-BA75-BC822AE4B29E
P2860
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Tenofovir plasma concentration ...... ts with normal renal function.
@ast
Tenofovir plasma concentration ...... ts with normal renal function.
@en
type
label
Tenofovir plasma concentration ...... ts with normal renal function.
@ast
Tenofovir plasma concentration ...... ts with normal renal function.
@en
prefLabel
Tenofovir plasma concentration ...... ts with normal renal function.
@ast
Tenofovir plasma concentration ...... ts with normal renal function.
@en
P2093
P2860
P356
P1476
Tenofovir plasma concentration ...... ts with normal renal function.
@en
P2093
A Calcagno
A D'Avolio
D Gonzalez de Requena
G Di Perri
M C Tettoni
P2860
P304
P356
10.1128/AAC.02434-12
P407
P577
2013-02-04T00:00:00Z